Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amarantus appoints board member

This article was originally published in Scrip

Executive Summary

Amarantus BioScience, which develops treatments and diagnostics for neurodegeneration and apoptosis diseases, has named Mark Benedyk to its board of directors. Dr Benedyk has severed as a corporate advisor to Sunnyvale, California-based Amarantus since 2011. Dr Benedyk is currently a managing partner at business and corporate development consultancy, Rila Partners. He serves on the strategic advisory board of KemPharm, is a director at the Center for Drug Research and Development Ventures and is a member of the translational medicine advisory board of the CNS Regenerative Medicine Foundation. With the addition of Dr Benedyk, Amarantus has four board members.

Advertisement
Advertisement
UsernamePublicRestriction

Register

SC020779

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel